Anaemia is an independent predictor of poor outcome in patients with chronic heart failure.

[1]  G. Fonarow,et al.  Anemia is associated with worse symptoms, greater impairment in functional capacity and a significant increase in mortality in patients with advanced heart failure. , 2002, Journal of the American College of Cardiology.

[2]  W. Rand,et al.  Reduced kidney function and anemia as risk factors for mortality in patients with left ventricular dysfunction. , 2001, Journal of the American College of Cardiology.

[3]  K. Swedberg,et al.  Guidelines for the diagnosis and treatment of chronic heart failure. , 2001, European heart journal.

[4]  I. Shapira,et al.  The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study. , 2001, Journal of the American College of Cardiology.

[5]  H. Stähelin,et al.  Anemia: an indicator for malnutrition in the elderly , 2001, Annals of Hematology.

[6]  P. Mohacsi,et al.  Serum erythropoietin in heart failure patients treated with ACE‐inhibitors or AT1 antagonists , 2000, European journal of heart failure.

[7]  R. Foley,et al.  Effects of anaemia on cardiovascular status. , 2000, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[8]  I. Shapira,et al.  The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations. , 2000, Journal of the American College of Cardiology.

[9]  D. Tsakiris.  Morbidity and Mortality Reduction Associated with the Use of Erythropoietin , 2000, Nephron.

[10]  S. Anker,et al.  The role of inflammatory mediators in chronic heart failure: cytokines, nitric oxide, and endothelin-1. , 2000, International journal of cardiology.

[11]  M. Packer,et al.  Can physicians always explain the results of clinical trials? A case study of amlodipine in heart failure. , 1999, The American journal of cardiology.

[12]  R. Means,et al.  Advances in the anemia of chronic disease. , 1999, International journal of hematology.

[13]  K. Grumbach,et al.  Congestive heart failure hospitalizations and survival in California: patterns according to race/ethnicity. , 1999, American heart journal.

[14]  Thomas D. Giles,et al.  Consensus recommendations for the management of chronic heart failure: Introduction , 1999 .

[15]  M. G. Levine,et al.  Functional assessment with electrocardiographic gated single-photon emission computed tomography improves the ability of technetium-99m sestamibi myocardial perfusion imaging to predict myocardial viability in patients undergoing revascularization. , 1999, The American journal of cardiology.

[16]  A R Nissenson,et al.  The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. , 1998, The New England journal of medicine.

[17]  P. Ponikowski,et al.  Wasting as independent risk factor for mortality in chronic heart failure , 1997, The Lancet.

[18]  David C. Murray,et al.  The impact of anemia on cardiomyopathy, morbidity, and and mortality in end-stage renal disease. , 1996, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[19]  B. Wikström,et al.  Renal anaemia treatment with recombinant human erythropoietin increases cardiac output in patients with ischaemic heart disease. , 1996, Scandinavian journal of urology and nephrology.

[20]  R. Carney,et al.  A multidisciplinary intervention to prevent the readmission of elderly patients with congestive heart failure. , 1995, The New England journal of medicine.

[21]  G. Condorelli,et al.  Blood levels of erythropoietin in congestive heart failure and correlation with clinical, hemodynamic, and hormonal profiles. , 1994, The American journal of cardiology.

[22]  W. Kannel,et al.  Hematocrit and the risk of cardiovascular disease--the Framingham study: a 34-year follow-up. , 1994, American heart journal.

[23]  E. Friedman,et al.  Changes in left ventricular size, wall thickness, and function in anemic patients treated with recombinant human erythropoietin. , 1992, American heart journal.

[24]  C. Sylvén,et al.  Induction of a reduction in haemoglobin concentration by enalapril in stable, moderate heart failure: a double blind study. , 1991, British heart journal.

[25]  S. Gottlieb,et al.  The erythrocyte sedimentation rate in congestive heart failure. , 1991, The New England journal of medicine.